Adjuvant stereotactic body radiotherapy following transarterial chemoembolization in patients with non‐resectable hepatocellular carcinoma tumours of ≥3 cm

ConclusionsThis retrospective study suggests that in patients with HCC tumours of ≥3 cm, treatment with TACE + SBRT provides a survival advantage over treatment with only TACE. Confirmation of this observation requires that the concept be tested in a prospective, randomized clinical trial.

Source: HPB: official journal of the International Hepato Pancreat Biliary Association - September 4, 2014 Category: Gastroenterology Authors: Rojymon Jacob, Falynn Turley, David T. Redden, Souheil Saddekni, Ahmed Kamel Abdel Aal, Kimberly Keene, Eddy Yang, Jessica Zarzour, David Bolus, J. Kevin Smith, Stephen Gray, Jared White, Devin E. Eckhoff, Derek A. DuBay Tags: Original Article Source Type: research